Yan Yu

机构：Tongji University, Shanghai University of Traditional Chinese Medicine, Shanghai Skin Disease Hospital · ORCID：0000-0003-0515-7747

发表论文 99 篇 · 总被引 2208 次 · h-index 24

代表论文

• Matrine suppresses lung cancer metastasis via targeting M2-like tumour-associated-macrophages polarization: Am J Cancer Res. 2021; 11(9): 4308-4328 (2026 · American Journal of Cancer Research · 被引 37)
• Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 16)
• Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial (2024 · Signal Transduction and Targeted Therapy · 被引 16)
• Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights (2025 · Frontiers in Immunology · 被引 14)
• Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial (2025 · The Lancet Respiratory Medicine · 被引 10)
• A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC. (2025 · Journal of Clinical Oncology · 被引 10)